- ►diabetesjournals.org A Rudich, S Vanounou, K Riesenberg, M Porat, A … - Diabetes, 2001 - Am Diabetes Assoc HIV protease inhibitors (HPIs) are potent antiretroviral agents clinically used in the management of
HIV infection. Recently, HPI therapy has been linked to the development of a metabolic syndrome in
which adipocyte insulin resistance ... Cited by 106 - Related articles - BL Direct - All 3 versions
R Ben-Romano, A Rudich, D Török, S Vanounou, K … - Aids, 2003 - journals.lww.com Objective: To test agent and cell-type specificity in insulin resistance induced by prolonged
exposure to HIV protease inhibitors (HPI), and to assess its relation to the direct, short-term
inhibition of insulin-stimulated ... Cited by 53 - Related articles - BL Direct - All 8 versions
- ►diabetesjournals.org LA Nolte, KE Yarasheski, K Kawanaka, J Fisher, N Le, … - Diabetes, 2001 - Am Diabetes Assoc In many patients with human immunodeficiency virus (HIV) treated with HIV protease inhibitors, a
complication develops that resembles abdominal obesity syndrome, with insulin resistance and glucose
intolerance that, in some cases, ... Cited by 74 - Related articles - BL Direct - All 5 versions
JM Lenhard, ES Furfine, RG Jain, O Ittoop, LA … - Antiviral research, 2000 - ncbi.nlm.nih.gov AIDS therapies employing HIV protease inhibitors (PIs) are associated with changes in fat
metabolism. However, the cellular mechanisms affected by PIs are not clear. Thus, the affects of PIs
on adipocyte differentiation were ... Cited by 141 - Related articles - All 4 versions
H Murata, PW Hruz, M Mueckler - Aids, 2002 - journals.lww.com Objectives: To determine the relative sensitivities of glucose transporter isoforms to the protease
inhibitor indinavir and to determine the kinetic mechanism of indinavir- mediated Glut4 isoform
inhibition. Methods: The rate of 2- ... Cited by 157 - Related articles - All 3 versions
H Murata, PW Hruz, M Mueckler - Journal of Biological Chemistry, 2000 - ASBMB Retroviral protease inhibitors used as therapy for HIV-1 infection have been causally associated
with serious metabolic side effects, including peripheral lipodystrophy, hyperlipidemia, insulin
resistance, and in some cases, ... Cited by 374 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org M Caron, M Auclair, C Vigouroux, M Glorian, C Forest, … - Diabetes, 2001 - Am Diabetes Assoc Protease inhibitors used in the treatment of HIV infection have been causally associated with
lipodystrophy and insulin resistance and were shown to alter adipocyte differentiation in cultured
cells. We aimed to delineate the ... Cited by 239 - Related articles - BL Direct - All 5 versions
- ►jbc.org P Dowell, C Flexner, PO Kwiterovich, MD Lane - Journal of Biological Chemistry, 2000 - ASBMB Many human immunodeficiency virus (HIV)-infected patients taking combination antiretroviral therapy
that includes HIV protease inhibitors experience atrophy of peripheral subcutaneous adipose tissue.
We investigated the effects of HIV ... Cited by 188 - Related articles - BL Direct - All 6 versions
B Zhang, K MacNaul, D Szalkowski, Z Li, J … - Journal of Clinical …, 1999 - Endocrine Soc Patients with AIDS who are receiving therapy with HIV protease inhibitors have been widely reported
to be afflicted with a syndrome characterized by lipodystrophy (fat redistribution favoring the
accumulation of abdominal and ... Cited by 155 - Related articles - BL Direct - All 5 versions
C Hadigan, S Borgonha, J Rabe, V Young, S … - Metabolism, 2002 - Elsevier Human immunodeficiency virus (HIV) lipodystrophy is associated with fat redistribution,
dyslipidemia, and insulin resistance; however, the mechanism of insulin resistance remains unknown.
We hypothesized that HIV-infected ... Cited by 91 - Related articles - BL Direct - All 6 versions
